These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21193857)

  • 1. Trial watch: hope renewed for strategy to raise HDL cholesterol.
    Nat Rev Drug Discov; 2011 Jan; 10(1):10. PubMed ID: 21193857
    [No Abstract]   [Full Text] [Related]  

  • 2. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 3. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
    Duriez P
    Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843
    [No Abstract]   [Full Text] [Related]  

  • 5. The DEFINE study: a bright future for CETP inhibitors?
    Katsiki N; Athyros VG; Mikhailidis DP
    Expert Opin Investig Drugs; 2011 Mar; 20(3):311-4. PubMed ID: 21235422
    [No Abstract]   [Full Text] [Related]  

  • 6. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.
    Holmes MV; Smith GD
    Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
    Kontush A; Guérin M; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 12. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon.
    Verma N; Figueredo VM
    Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 15. HDL cholesterol and atherosclerosis.
    Mazzone T
    Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?
    Devaraj S; Jialal I
    Metab Syndr Relat Disord; 2011 Jun; 9(3):163-5. PubMed ID: 21557663
    [No Abstract]   [Full Text] [Related]  

  • 17. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA; Nicholls SJ
    Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The failure of torcetrapib: what have we learned?
    Joy TR; Hegele RA
    Br J Pharmacol; 2008 Aug; 154(7):1379-81. PubMed ID: 18536741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.